RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTIONREALITY SUPPS RESEARCH NOTES
Compound primer

What is BPC-157? Structure, origin and the research models that have examined it

6 Oct 2026Reality Supps Research Desk3 min read

A primer on the pentadecapeptide BPC-157: where the sequence comes from, how it is made, and what the in-vitro and animal literature has studied.

BPC-157 is the most frequently cited compound in the research-peptide literature and the most frequently misdescribed. This note covers what it is and what has actually been studied, without the claims that usually accompany it.

Structure and origin

BPC-157 is a synthetic peptide of fifteen amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of about 1,419 daltons. The “BPC” stands for Body Protection Compound, the name given by a group at the University of Zagreb to a protein they isolated from human gastric juice in the early 1990s. BPC-157 is a fragment of that protein, chosen because it was the shortest segment that retained activity in the group’s assays.

The compound is made by solid-phase peptide synthesis rather than extracted from tissue. Two forms appear in the literature: the acetate salt and an arginate salt described as more stable in solution. Research suppliers typically list the acetate form.

What the research has examined

The published work is dominated by one laboratory group and is almost entirely in cell culture and rodent models. Three lines of investigation recur.

Tendon and muscle injury models. Chang and colleagues (2011) studied the peptide in cultured tendon fibroblasts and reported effects on cell outgrowth, survival and migration, with changes in growth-hormone receptor expression. Rodent studies from the Zagreb group have used transected Achilles tendon, crushed quadriceps and similar injury models.

Vascular signaling. Several papers describe interaction with the nitric-oxide system and with VEGFR2 signaling in cell and animal models, which the authors connect to angiogenesis in injured tissue.

Gastrointestinal models. The earliest studies, consistent with the compound’s origin, used rodent models of gastric and intestinal lesions. Later papers extended the same approach to a brain–gut axis framing.

What the literature does not contain is as important as what it does. There are no published controlled human trials of BPC-157. One Phase 1 study of an oral formulation is registered but unpublished. The compound is not approved by any regulator for any use, and the World Anti-Doping Agency lists it as prohibited in sport.

How to evaluate a BPC-157 lot

Because the sequence is short and well characterized, identity by mass spectrometry is straightforward: the main peak should correspond to about 1,419 Da. Purity by HPLC above 98 percent is routine for a competent synthesis. The common failure is not purity but net content, where a vial labeled 10 mg contains materially less, so a certificate that reports fill weight is worth more than one that reports purity alone.

References

  • Chang, C. H., et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology 110 (2011): 774–780.
  • Seiwerth, S., et al. “BPC 157 and standard angiogenic growth factors.” Current Pharmaceutical Design 24 (2018): 1972–1989.
  • Sikiric, P., et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Current Neuropharmacology 14 (2016): 857–865.
  • World Anti-Doping Agency, Prohibited List (2026), section S0.
Research use only · Not for human or animal consumption · Not medical advice · This note summarizes published in-vitro and animal research and makes no claims about effects in humans.